United Cannabis (CNABQ) 10-Q 19 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 19, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Entity Registrant Name	'United Cannabis Corp	'
Entity Central Index Key	'0001436161	'
Current Fiscal Year End Date	'--12-31	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Units Outstanding	'	43,620,000

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$337,544	$32,414
Investments in non-marketable equity securities	300,000	'
Due from related party	'	8,862
Assets of discontinued operations	'	17,616
Total current assets	637,544	58,892
Investments in non-marketable equity securities	593,750	'
Total assets	1,231,294	58,892
Current liabilities:	'	'
Accounts payable	11,872	'
Deferred revenue	893,750	'
Convertible note payable, related party	'	50,000
Total current liabilities	905,622	50,000
Stockholders' equity:	'	'
Preferred stock, no par value; 10,000,000 shares authorized; none issued and outstanding	'	'
Common stock, no par value; 100,000,000 shares authorized; 43,620,000 and 6,020,000 issued and outstanding, respectively	1,115,495	165,495
Accumulated deficit	-789,823	-156,603
Total stockholders' equity	325,672	8,892
Total liabilities and stockholders' equity	$1,231,294	$58,892

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
CONDENSED BALANCE SHEETS [Abstract]	'	'
Preferred stock, no par value	'	'
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, no par value	'	'
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,620,000	6,020,000	[1]
Common stock, shares outstanding	43,620,000	6,020,000	[1]
[1]	The number of outstanding common shares has been adjusted for a four for one forward split that occurred on March 21, 2014

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
CONDENSED STATEMENTS OF OPERATIONS [Abstract]	'	'		'		'
Revenues	'	'		'		'
Operating expenses:	'	'		'		'
Sales and marketing	68,158	'		74,158		'
Research and development	66,053	'		76,053		'
General and administrative	360,664	6,650		424,142		10,777
Total operating expenses	494,875	6,650		574,353		10,777
Loss from operations	-494,875	-6,650		-574,353		-10,777
Other income:	'	'		'		'
Interest income	25	'		25		'
Total other income	25	'		25		'
Loss from continuing operations	-494,850	-6,650		-574,328		-10,777
Net income (loss) from discontinued operations	'	11,627		-58,892		19,822
Net (loss) income	($494,850)	$4,977		($633,220)		$9,045
Net loss per share from continuing operations:	'	'		'		'
Basic and diluted	($0.01)	$0	[1]	($0.02)		$0	[1]
Net income ( loss) per share from discontinued operations:	'	'		'		'
Basic and diluted	'	$0	[1]	$0	[1]	$0	[1]
Net (loss) income per common share:	'	'		'		'
Basic and diluted	($0.01)	$0	[1]	($0.02)		$0	[1]
Basic and diluted weighted-average common shares outstanding:	43,620,000	6,020,000	[2]	32,592,376		6,020,000	[2]
[1]	Denotes income or loss of less than $0.01 per share.
[2]	The number of outstanding common shares has been adjusted for a four for one forward split that occurred on March 21, 2014

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating activities:	'	'
Net (loss) income	($633,220)	$9,045
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:	'	'
Depreciation - assets of discontinued operations	'	13,313
Loss on sale of assets of discontinued operations	15,704	'
Management fees and reimbursement of expenses, related parties, net of discontinued operations	'	3,191
Changes in operating assets and liabilities:	'	'
Accounts receivable	'	-1,669
Due from related party	10,774	-18,056
Inventory	'	-13,916
Due to related party	'	7,544
Accounts payable and accrued expenses	11,872	-6,113
Net cash provided by (used in) operating activities	-594,870	-6,661
Investing activities:	'	'
Equipment purchases related to discontinued operations	'	-14,408
Net cash provided by (used in) investing activities	'	-14,408
Financing activities:	'	'
Notes payable, related parties	'	-50,000
Issuance of common shares	900,000	'
Net cash provided by (used in) financing activities	900,000	-50,000
Net increase in cash	305,130	-71,069
Cash, beginning of period	32,414	76,445
Cash, end of period	337,544	5,376
Supplemental schedule of cash flow information:	'	'
Cash paid for interest	'	'
Cash paid for income taxes	'	'
Supplemental disclosure of non-cash investing and financing activities:	'	'
Investment in non-marketable equity securities for deferred services	893,750	'
Conversion of note payable, related party into common stock	($50,000)	'

NATURE_OF_OPERATIONS_AND_BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2014
NATURE OF OPERATIONS AND BASIS OF PRESENTATION [Abstract]	'
NATURE OF OPERATIONS AND BASIS OF PRESENTATION	'
	NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION
	Current Operations and Background - United Cannabis Corporation ("we", "our", "us" or "UCC") a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007.  UCC was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCC, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation.
	On March 26, 2014, we entered into a License Agreement with Earnest Blackmon ("Blackmon"), Tony Verzura ("Verzura") and Chad Ruby ("Ruby") pursuant to which Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.
	In connection with this transaction:
		·	Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called A.C.T. Now, security, regulatory compliance, and any other methods and processes which relate to the cannabis industry.
		·	The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement.
		·	Blackmon, Verzura and Ruby were appointed to our board of directors effective April 8, 2014.
		·	Blackmon was elected as our President, Ruby was elected as Chief Operating Officer and Verzura was elected as Vice President. On February 27, 2014, Paul Enright became our President, CFO, and Secretary, Treasurer and sole member of the board (see also Note 8). On March 26, 2014, in connection with this transaction, Mr. Enright resigned as President. On June 24, 2014, Mr. Enright resigned his position as CEO, was elected as VP of Business Development and Corporate Relations and Blackmon was elected as our CEO.
		·	A total of 41,690,000 previously outstanding shares of common stock were cancelled, and as a result of this transaction there are now a total of 43,620,000 shares of common stock outstanding.
	As a result of this transaction our business plan has changed.  We plan to create partnerships with local businessmen, entrepreneurs, scientists and others, both domestically and internationally, for the purpose of cultivating cannabis-based products worldwide.
	For example, we plan to enter into licensing and consulting agreements with partners who desire to license our entire turnkey seed-to-sale business model in jurisdictions where it is legal to do so, and we plan to typically receive a percentage of their gross revenues as our fee.  In addition to licensing our intellectual property, we will offer consulting on the design and buildout of cultivation facilities, we will provide training and staffing services, and we will assist our partners in finding the right locations for cultivation facilities.  We will provide our genetic catalogue which includes over 15 CBD strains, over 150 THC strains and over 30 Cannabis Cup winners.
	We will also provide access to our full range of extracted/infused medical products.  We will license to our partners the intellectual property for whole plant activated oils, smokable concentrates, infused products, topical lotions, pills, sublingual transdermal patches and our partners will have access to any future technology or products we develop.
	Our goals are to establish strong cultivation positions through our local partners in markets where it is legal and use these revenues to develop new cannabinoid based drugs for clinical FDA approval patents.
	On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. ("MTA"), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.
	Government Regulation - Marijuana is a Schedule-I controlled substance and is illegal under federal law.  Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal laws.
	As of August 15, 2014, 23 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of Colorado and Washington approved ballot measures in November 2103 to legalize cannabis for adult recreational use.  The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana.   However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously.  Any such change in the federal government's enforcement of current federal laws could cause significant financial damage to us.  While we do not intend to harvest, distribute or sell cannabis, we may be irreparably harmed by a change in enforcement by the Federal or state governments.
	Basis of Presentation - We prepared these condensed financial statements in accordance with accounting principles generally accepted in the United States ("GAAP"). The accompanying unaudited interim condensed financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. Operating results for the three and six month periods ended June 30, 2014 and 2013 are not necessarily indicative of the results for the full year. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed financial statements should be read in conjunction with the audited financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2013.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.
	We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
	Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of June 30, 2014 and December 31, 2013.
	Accounts Receivable - We plan to extend credit to our customers. Collateral generally will not be required. Credit losses will be provided for in the financial statements based on our evaluation of historical and current industry trends. Although we expect to fully collect amounts due, actual collections may differ from estimated amounts. We will estimate an allowance for doubtful accounts based upon a percentage of revenue earned.
	Investments in Non-Marketable Equity Securities - Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows.
	Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.
	Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.
	Revenue Recognition - We recognize revenue in accordance with ASC 605, "Revenue Recognition" which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.
	Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.
	Advertising Costs - All advertising costs are expensed as incurred.
	Research and Development Expense - Research and development ("R&D") costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.
	Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.
	Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.
	We follow the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 740 Income taxes (ASC 740). As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.
	Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260 Earnings per Share (ASC 260). Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive shares of common stock that are not anti-dilutive.
	Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.
	Financial Instruments - Our financial instruments consist of cash, accounts receivable, investments in non-marketable equity securities, accounts payable and notes payable to related parties. The carrying values of cash, accounts receivable and accounts payable are representative of their fair values due to their short-term maturities. Investments in non-marketable equity securities are carried at cost. Notes payable to related parties approximates fair value because of the short-term nature of these financial instruments.
	Recently Issued Accounting Pronouncements - From time to time, the Financial Accounting Standards Board ("FASB") or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification ("ASC") are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

GOING_CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2014
GOING CONCERN [Abstract]	'
GOING CONCERN	'
	NOTE 3 - GOING CONCERN
	Our condensed financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the six months ended June 30, 2014, we incurred losses of $633,220 and used cash of $594,870 in our operating activities. As at June 30, 2014, we had a working capital deficit of $268,078 and an accumulated deficit of $789,823.  Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

INVESTMENTS_IN_NONMARKETABLE_E

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	6 Months Ended
	Jun. 30, 2014
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]	'
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	'
	NOTE 4 - INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES
	On May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD RX Inc. ("WMD"), a Canadian private company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The shares represent a 4.29% equity investment in WMD and we do not have significant influence over the investee. We recorded our investment in these non-marketable equity securities at the estimated cost, based on our estimate of the fair value of the securities we received on the date of the transaction.
	The warrants entitle us to purchase WMD shares for CDN $0.50 each for a period of six months from the date the warrant is issued. In addition, we are required to exercise all of these warrants if the holders of our Series A Warrants (see Note 8 below) exercise a minimum of 800,000 of our Series A Warrants prior to the expiration of the WMD warrants.
	The WMD common shares were recorded at $0.50 per share based on WMD's most recent sale of their common shares prior to the date of the transaction (CDN $0.50) and their most recent sale of common shares subsequent to this transaction (CDN $0.60). The warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the three and six months ended June 30, 2014:
	Risk free interest rate	0.60%
	Expected term (years)	0.5
	Expected volatility	70%
	Expected dividends	0%
	The $300,000 fair value assigned as the cost to the WMD warrants has been classified as a current asset as the warrants expire after six months, while the $593,750 assigned to the cost of the WMD common shares has been classified as a long term assets as these shares do not expire.

EQUIPMENT

EQUIPMENT	6 Months Ended
	Jun. 30, 2014
EQUIPMENT [Abstract]	'
EQUIPMENT	'
	NOTE 5 - EQUIPMENT
	Our equipment, consists of the following at:
		June 30,		December 31,
		2014		2013
	Equipment	$	-	$	131,584
	Less accumulated depreciation		-		(113,968	)
		$	-	$	17,616

RELATED_PARTY_NOTE_PAYABLE

RELATED PARTY NOTE PAYABLE	6 Months Ended
	Jun. 30, 2014
RELATED PARTY NOTE PAYABLE [Abstract]	'
RELATED PARTY NOTE PAYABLE	'
	NOTE 6 - RELATED PARTY NOTE PAYABLE
	In December 2011, we entered into a Revolving Promissory Note (the "Note") with Ms. Stoppenhagen, our former president and director. Under the terms of the Note, Ms. Stoppenhagen agreed to advance us, from time to time and at our request, amounts up to an aggregate of $100,000 until December 31, 2013, with all advances be paid on or before December 31, 2013, and interest accruing from the date of any advances on any principal amount withdrawn, and on unpaid interest thereon, at the rate of six percent (6%) per annum, compounded annually. As of June 30, 2014 and December 31, 2013, nothing was owed under the note.

CONVERTIBLE_NOTE_PAYABLE_RELAT

CONVERTIBLE NOTE PAYABLE - RELATED PARTY	6 Months Ended
	Jun. 30, 2014
CONVERTIBLE NOTE PAYABLE - RELATED PARTY [Abstract]	'
CONVERTIBLE NOTE PAYABLE - RELATED PARTY	'
	NOTE 7 - CONVERTIBLE NOTE PAYABLE - RELATED PARTY
	On September 30, 2013, we issued a Convertible Note (the "Convertible Note") for $50,000 to NYX Capital Advisors, Inc. ("NYX") in connection with $50,000 cash paid by NYX. The Convertible Note bears no interest and was convertible at any time, at the option of the holder, into 10,000,000 shares of our common stock at $0.005 per share. The Convertible Note was converted on February 24, 2014.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 8 - STOCKHOLDERS' EQUITY
	Change of control
	On February 27, 2014, NYX and Mr. Enright entered into a Stock Purchase Agreement, pursuant to which NYX sold to Mr. Enright an aggregate of 10,000,000 shares of our common stock, representing approximately 87% of our issued and outstanding shares as of that date.
	Stock split
	On March 21, 2014, we effected a four-for-one stock split of our common stock in the form of a stock dividend of three shares of common stock for each share of common stock outstanding to stockholders of record on March 19, 2014.
	Equity offering
	On March 26, 2014, we sold 600,000 units for a total amount of $900,000 to 45 accredited investors. Each Unit consisted of one share of our common stock, two A Warrants and three B Warrants. Each A Warrant entitles the holder to purchase one share of our common stock at a price of $7.50 per share during the two year period commencing April 1, 2014, and the A Warrants are callable once our common stock has traded at a price of at least $15 for 20 consecutive trading days. Each B Warrant entitles the holder to purchase one share of our common stock at a price of $15.00 per share during the three year period commencing April 1, 2014, and the B Warrants are callable once our common stock has traded at a price of at least $22 for 20 consecutive trading days.
	Change in Authorized Share Capital
	Effective May 2, 2014, we increased the authorized number of our preferred shares from five million to ten million and the authorized number of our common shares from 50 million to 100 million. At the same time we also changed the par value of both our preferred and common stock from $0.001 per share to no par value per share.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 9 - COMMITMENTS AND CONTINGENCIES
	Contractual Obligations and Commercial Commitments
	On May 6, 2014, we entered into a consultancy agreement with a third party that has a six month term which can be renewed and/or extended by mutual agreement. The agreement provides for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement.
	Legal Proceedings
	We were not subject to any legal proceedings during the three and six months ended June 30, 2014, and, to the best of our knowledge, no legal proceedings are pending or threatened.

DISCONTINUED_OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2014
DISCONTINUED OPERATIONS [Abstract]	'
DISCONTINUED OPERATIONS	'
	NOTE 10 -DISCONTINUED OPERATIONS
	On March 31, 2014 we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. ("MTA"), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. See Note 1 for further detail on our change in operations.
	The following chart details our loss from discontinued operations for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014			2013
	Revenues	$	-	$	31,691	$	20,684		$	58,866
	Operating expenses:
	Selling, general and administrative		-		13,184		63,872			25,731
	Depreciation		-		6,880		-			13,313
	Loss on disposal of assets		-		-		15,704			-
	Total operating expenses		-		20,064		79,576			39,044
	Income (loss) from discontinued operations, before income taxes		-		11,627		(58,892	)		19,822
	Provision for income taxes		-		-		-			-
	Income (loss) from discontinued operations, net of income taxes	$	-	$	11,627	$	(58,892	)	$	19,822
	Our assets held for sale consist of the following and are included in assets of discontinued operations on our condensed balance sheets:
		June 30,		December 31,
		2014		2013
	Equipment	$	-	$	17,616

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 11 - SUBSEQUENT EVENTS
	On August 15, 2014, Mr. Enright, who served as our Vice President of Business Development and Corporate Relations and as a Director, resigned his positions as an officer and director, but he will continue to be employed by UCC.
	On August 13, 2014, we entered into a Securities Purchase Agreement with Typenex Co-Investment, LLC ("Typenex"), for the sale of a 10% convertible note in the principal amount of $1,657,500 (which includes Typenex legal expenses in the amount of $7,500 and a $150,000 original issue discount) (the "Note") for $1,500,000, consisting of $250,000 paid in cash at closing and five secured promissory notes, aggregating $1,250,000, bearing interest at the rate of 8% per annum, each note maturing in twenty-five months from August 13, 2014 (the "Investor Notes"). The Investor Notes allow for prepayment, without penalty, all or portion of the outstanding balance along with accrued but unpaid interest at any time prior to maturity. We have no obligation to pay Typenex any amounts on the unfunded portion of the Note.
	The Note bears interest at the rate of 10% per annum. All interest and principal must be repaid on September 13, 2016. The Note is convertible into common stock, at Typenex's option, at the lesser of (i) $3.00, and (ii) 70% (the "Conversion Factor") of the average of the three (3) lowest Closing Bid Prices in the twenty (20) Trading Days immediately preceding the applicable Conversion, provided that if at any time the average of the three (3) lowest Closing Bid Prices in the twenty (20) Trading Days immediately preceding any date of measurement is below $1.00, then in such event the then-current Conversion Factor shall be reduced to 65% for all future Conversions, subject to other reductions set forth in the Note. In the event we elect to prepay all or any portion of the Note, we are required to pay to Typenex an amount in cash equal to 125% multiplied by the sum of all principal, interest and any other amounts owing. The Note is secured by all of our assets.
	In accordance with ASC 855-10 we have analyzed its operations subsequent to June 30, 2014 to the date these condensed financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these condensed financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	6 Months Ended
	Jun. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Use of Estimates	'
	Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.
	We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of June 30, 2014 and December 31, 2013.
Accounts Receivable	'
	Accounts Receivable - We plan to extend credit to our customers. Collateral generally will not be required. Credit losses will be provided for in the financial statements based on our evaluation of historical and current industry trends. Although we expect to fully collect amounts due, actual collections may differ from estimated amounts. We will estimate an allowance for doubtful accounts based upon a percentage of revenue earned.
Investments in Non-Marketable Equity Securities	'
	Investments in Non-Marketable Equity Securities - Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows.
Inventory	'
	Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.
Equipment	'
	Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.
Revenue Recognition	'
	Revenue Recognition - We recognize revenue in accordance with ASC 605, "Revenue Recognition" which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.
Deferred Revenue	'
	Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.
Advertising Costs	'
	Advertising Costs - All advertising costs are expensed as incurred.
Research and Development Expense	'
	Research and Development Expense - Research and development ("R&D") costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.
Selling, General and Administrative Expenses	'
	Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.
Income Taxes	'
	Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.
	We follow the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 740 Income taxes (ASC 740). As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.
Net Income (Loss) Per Share	'
	Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260 Earnings per Share (ASC 260). Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive shares of common stock that are not anti-dilutive.
Concentration of Credit Risk	'
	Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.
Financial Instruments	'
	Financial Instruments - Our financial instruments consist of cash, accounts receivable, investments in non-marketable equity securities, accounts payable and notes payable to related parties. The carrying values of cash, accounts receivable and accounts payable are representative of their fair values due to their short-term maturities. Investments in non-marketable equity securities are carried at cost. Notes payable to related parties approximates fair value because of the short-term nature of these financial instruments.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements - From time to time, the Financial Accounting Standards Board ("FASB") or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification ("ASC") are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

INVESTMENTS_IN_NONMARKETABLE_E1

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2014
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]	'
Schedule of Fair Value Assumptions Used to Value Warrants	'
	The warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the three and six months ended June 30, 2014:
	Risk free interest rate	0.60%
	Expected term (years)	0.5
	Expected volatility	70%
	Expected dividends	0%

EQUIPMENT_Tables

EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2014
EQUIPMENT [Abstract]	'
Schedule of Equipment	'
	Our equipment, consists of the following at:
		June 30,		December 31,
		2014		2013
	Equipment	$	-	$	131,584
	Less accumulated depreciation		-		(113,968	)
		$	-	$	17,616

DISCONTINUED_OPERATIONS_Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2014
DISCONTINUED OPERATIONS [Abstract]	'
Schedule of Loss from Discontinued Operations	'
	The following chart details our loss from discontinued operations for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014			2013
	Revenues	$	-	$	31,691	$	20,684		$	58,866
	Operating expenses:
	Selling, general and administrative		-		13,184		63,872			25,731
	Depreciation		-		6,880		-			13,313
	Loss on disposal of assets		-		-		15,704			-
	Total operating expenses		-		20,064		79,576			39,044
	Income (loss) from discontinued operations, before income taxes		-		11,627		(58,892	)		19,822
	Provision for income taxes		-		-		-			-
	Income (loss) from discontinued operations, net of income taxes	$	-	$	11,627	$	(58,892	)	$	19,822
	Our assets held for sale consist of the following and are included in assets of discontinued operations on our condensed balance sheets:
		June 30,		December 31,
		2014		2013
	Equipment	$	-	$	17,616

NATURE_OF_OPERATIONS_AND_BASIS1

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) (USD $)	1 Months Ended
	Mar. 31, 2014	Jun. 30, 2014	Mar. 26, 2014	Dec. 31, 2013
NATURE OF OPERATIONS AND BASIS OF PRESENTATION [Abstract]	'	'	'	'
Amount of payable owed to former officer and director, exchanged for assets sold	$15,000	'	'	'
Number of common shares issued in exchange for certain intellectual property	38,690,000	'	'	'
Total number of common shares previously outstanding, cancelled during period	'	'	41,690,000	'
Common stock, shares outstanding	'	43,620,000	43,620,000	6,020,000	[1]
[1]	The number of outstanding common shares has been adjusted for a four for one forward split that occurred on March 21, 2014

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014
			Minimum [Member]	Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'
Cash equivalents	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Estimated useful lives of equipment	'	'	'3 years	'5 years

GOING_CONCERN_Details

GOING CONCERN (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
GOING CONCERN [Abstract]	'	'	'	'	'
Net loss (income)	$494,850	($4,977)	$633,220	($9,045)	'
Net cash used in operating activities	'	'	594,870	6,661	'
Working capital deficit	268,078	'	268,078	'	'
Accumulated deficit	$789,823	'	$789,823	'	$156,603

INVESTMENTS_IN_NONMARKETABLE_E2

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Narrative) (Details) (WeedMD RX Inc. ("WMD") [Member])	1 Months Ended
	31-May-14	31-May-14	1-May-14	1-May-14
	USD ($)	CAD	USD ($)	CAD
Schedule of Cost-method Investments [Line Items]	'	'	'	'
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500	'	'	'
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000	'	'	'
Equity investment	4.29%	'	'	'
Exercise price of warrants received to purchase shares	'	0.5	'	'
Minimum number of Series A Warrants exercised that would require all warrants received to be exercised	800,000	'	'	'
Common shares, price per share	'	0.6	$0.50	0.5
Warrants, price per warrant	$0.10	'	'	'
Value assigned to the cost of the common shares classified as a long term asset	$593,750	'	'	'
Fair value assigned as the cost to the warrants classified as a current asset	$300,000	'	'	'

INVESTMENTS_IN_NONMARKETABLE_E3

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Schedule of Assumptions) (Details) (Cost-method Investments [Member], Warrant [Member], WeedMD RX Inc. ("WMD") [Member])	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Cost-method Investments [Member] | Warrant [Member] | WeedMD RX Inc. ("WMD") [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Pricing model	'Black Scholes	'Black Scholes
Risk free interest rate	0.60%	0.60%
Expected term	'6 months	'6 months
Expected volatility	70.00%	70.00%
Expected dividends	0.00%	0.00%

EQUIPMENT_Details

EQUIPMENT (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
EQUIPMENT [Abstract]	'	'
Equipment	'	$131,584
Less accumulated depreciation and amortization	'	-113,968
Equipment, net	'	$17,616

RELATED_PARTY_NOTE_PAYABLE_Det

RELATED PARTY NOTE PAYABLE (Details) (USD $)	1 Months Ended
	Dec. 31, 2011	Jun. 30, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'	'
Convertible note payable, related party	'	'	$50,000
Former President [Member] | Revolving Promissory Note [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Debt instrument, face amount	100,000	'	'
Debt instrument, interest rate	6.00%	'	'
Debt instrument, maturity date	31-Dec-13	'	'
Convertible note payable, related party	'	'	'

CONVERTIBLE_NOTE_PAYABLE_RELAT1

CONVERTIBLE NOTE PAYABLE - RELATED PARTY (Details) (Convertible Note [Member], USD $)	1 Months Ended	6 Months Ended
	Sep. 30, 2013	Jun. 30, 2014
Convertible Note [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	$50,000	'
Debt instrument, interest rate	0.00%	'
Number of common stock shares debt instrument can be converted to	10,000,000	'
Debt conversion, price per share	$0.01	'
Debt instrument, conversion date	'	24-Feb-14

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	1 Months Ended
	Mar. 31, 2014	Feb. 28, 2014	Jun. 30, 2014	2-May-14	1-May-14	Dec. 31, 2013
STOCKHOLDERS' EQUITY [Abstract]	'	'	'	'	'	'
Common stock sold under stock purchase agreement, representing approximately 87% of the issued and outstanding shares of the Company	'	10,000,000	'	'	'	'
Number of units sold through equity offering	600,000	'	'	'	'	'
Proceeds from sale of units	$900,000	'	'	'	'	'
Per share price A Warrant holders can purchase each share of the Company's common stock during the two year period commencing April 1, 2014	$7.50	'	'	'	'	'
Per share price B Warrant holders can purchase each share of the Company's common stock during the three year period commencing April 1, 2014	$15	'	'	'	'	'
Preferred stock, shares authorized	'	'	10,000,000	10,000,000	5,000,000	10,000,000
Preferred stock, par value per share	'	'	'	'	$0.00	'
Preferred stock, no par value	'	'	'	'	'	'
Common stock, shares authorized	'	'	100,000,000	100,000,000	50,000,000	100,000,000
Common stock, par value per share	'	'	'	'	$0.00	'
Common stock, no par value	'	'	'	'	'	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	1 Months Ended
	31-May-14
Commitments and Contingencies Disclosure [Abstract]	'
Consultancy agreement, term	'6 months
Consultancy agreement, initial payment	$50,000
Consultancy agreement, additional payments	$50,000
Shares issued for consultancy agreement	100,000

DISCONTINUED_OPERATIONS_Detail

DISCONTINUED OPERATIONS (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Mar. 31, 2014	Dec. 31, 2013
DISCONTINUED OPERATIONS [Abstract]	'	'	'	'	'	'
Amount of payable owed to former officer and director, exchanged for assets sold	'	'	'	'	$15,000	'
Revenues	'	31,691	20,684	58,866	'	'
Operating expenses:	'	'	'	'	'	'
Selling, general and administrative	'	13,184	63,872	25,731	'	'
Depreciation	'	6,880	'	13,313	'	'
Loss on disposal of assets	'	'	15,704	'	'	'
Total operating expenses	'	20,064	79,576	39,044	'	'
Income (loss) from discontinued operations, before income taxes	'	11,627	-58,892	19,822	'	'
Provision for income taxes	'	'	'	'	'	'
Income (loss) from discontinued operations, net of income taxes	'	11,627	-58,892	19,822	'	'
Equipment	'	'	'	'	'	$17,616

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], Typenex Co-Investment, LLC [Member], USD $)	1 Months Ended
	Aug. 31, 2014
Convertible Note, Including Legal Expenses and Original Issue Discount [Member]	'
Subsequent Event [Line Items]	'
Debt instrument, face amount	$1,657,500
Legal expenses	7,500
Original issue discount	150,000
Proceeds from convertible debt	250,000
Debt instrument, interest rate	10.00%
Debt instrument, issuance date	13-Aug-14
Debt instrument, maturity date	13-Sep-16
Convertible Note, Excluding Legal Expenses and Original Issue Discount [Member]	'
Subsequent Event [Line Items]	'
Debt instrument, face amount	1,500,000
Five Secured Promissory Notes Not Yet Paid [Member]	'
Subsequent Event [Line Items]	'
Debt instrument, face amount	$1,250,000
Debt instrument, interest rate	8.00%
Debt instrument, term	'25 months
Debt instrument, issuance date	13-Aug-14